Oral therapies for the treatment of pulmonary arterial hypertension: A population-based cost-minimization analysis

Applied Health Economics and Health Policy

Volumn 7, Issue 1, 2009, Pages 43-59

  Dranitsaris, George ^a   Mehta, Sanjay ^b  

^a Augmentium Pharma Consulting   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; PLACEBO; SILDENAFIL; SITAXSENTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CANADA; CLINICAL TRIAL; CONSULTATION; DIAGNOSTIC PROCEDURE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; LABORATORY TEST; LIVER TOXICITY; META ANALYSIS; MORTALITY; PREVALENCE; PULMONARY HYPERTENSION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; CANADA; COSTS AND COST ANALYSIS; DRUG COSTS; HUMANS; HYPERTENSION, PULMONARY; ISOXAZOLES; PHENYLPROPIONATES; PIPERAZINES; PLACEBOS; PURINES; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; SULFONES; THIOPHENES; TREATMENT OUTCOME;

EID: 70349107217     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/bf03256141     Document Type: Article

References (35)

1. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence based clinical practice guidelines. Chest 2004; 126: 78-92
2. Gabbay E, Reed A, Williams TJ. Assessment and treatment of pulmonary arterial hypertension. Intern Med J 2007; 37: 38-48
3. D Alonzo GE, Barst RJ, Ayers SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective study. Ann Intern Med 1991; 115: 343-349
4. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol with conventional therapy for pulmonary arterial hypertension. N Engl J Med 1996; 334: 296-301
5. Galié N, Seeger W, Naeije R, et al. Comparative analysis of clinical trials and evidence based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 81-8S
6. McLaughlin VV, Shillington A, Risk S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482
7. Sitbon O, Humbert M, Jaï s X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111
8. Langleben D, Archer S, Granton J, et al. Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension. Can J Cardiol 2005; 21: 909-914 (Pubitemid 41582311)
9. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007; 30: 1103-1110
10. Torres F. Systematic review of randomized, double blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension. Int J Clin Pract 2007; 61: 1756-1765
11. Park MH. Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. Catheter Cardiovasc Interv 2008; 71: 205-213
12. Rubin L, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903 (Pubitemid 34984638)
13. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-447
14. Galié N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157 (Pubitemid 41653106)
15. Naeije R, Huez S. Expert opinion on available options treating pulmonary arterial hypertension. Expert Opin Pharmacother 2007; 8: 2247-2265
16. Barst RJ. A review of pulmonary arterial hypertension: role of ambrisentan. Vasc Health Risk Manag 2007; 3: 11-22
17. Galié N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-3019
18. Oudiz RJ. Long term ambrisentan therapy provides sustained benefit in patients with pulmonary arterial hypertension [abstract]. Chest 2007; 132: 474s
19. Torres F. Ambrisentan improved multiple scales of the SF-36 health survey in patients with pulmonary arterial hypertension [abstract]. Chest 2007; 132: 634s
20. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009; 135: 122-129
21. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programs. Oxford: Oxford University Press, 1987
22. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030
23. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-109
24. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917-1928
25. Statistics Canada. Quarterly demographic estimates: July to September 2007 [online]. Available from URL: http:// dsp-psd.pwgsc.gc.ca/collection-2007/ statcan/91-002-X/91-002-XIE2007003.pdf [Accessed 2008 Jun 21]
26. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin- A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049-2056
27. Simonneau G, Rubin LJ, Galié N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521-530
28. Einarson TR, Granton JT, Vincente C, et al. Cost effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis. Can Resp J 2005; 12: 419-425
29. Olschewski H, Galié N, Kramer M, et al. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: results of the ARIES-2 study [abstract]. 102nd International Conference of the American Thoracic Society; 2006 May 19-24; San Diego (CA)
30. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebocontrolled study. Lancet 2001; 358: 1119-1123 (Pubitemid 32971843)
31. Galié N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patient with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54
32. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116: 1555-1562
33. Wlodarczyk JH, Cleland LG, Keogh AM, et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. Pharmacoeconomics 2006; 24: 903-915
34. Highland KB, Strange C, Mazur J, et al. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 2003; 124: 2087-2092
35. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension study. Am J Respir Crit Care Med 2005; 171: 1292-1297